DRMA

Dermata Therapeutics

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 1

Sell signal 0

EPS Beats Expectation

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About DRMA

Dermata Therapeutics, Inc.

A clinical-stage biotech company focusing on the treatment of medical and aesthetic skin conditions

Industry

Pharmaceutical

Established Date

Invalid Date

Listing Date

08/13/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.dermatarx.com

Security Type

Common stock

Office address

3525 Del Mar Heights Rd., #322, San Diego, CA 92130

Business

Introduction

Dermata Therapeutics, Inc., in Delaware in December 2014. They are a clinical-stage medical dermatology company focused on identifying, developing and commercializing innovative drug candidates for the treatment of medical and aesthetic skin diseases and conditions, which the company believes represent a significant market opportunity due to the lack or non-existence of current therapies.

Company Financials

EPS

DRMA has released its 2023 Q3 earnings. EPS was reported at -0.54, versus the expected -0.63, beating expectations. The chart below visualizes how DRMA has performed over recent quarters, highlighting trends in earnings surprises.